| Corona 19 vaccine © AFP=News1 |
Reuters reported on the 4th that the UK has entered a mixed vaccine trial to catch the mutant virus. The world’s leading pharmaceutical companies have succeeded in making the Corona 19 virus vaccine, but it is to prepare for this as mutations are occurring frequently.
UK Vaccine Development Minister Nadim Jahawi said in an interview with Skynews that “it is very unlikely that the current vaccines will be effective against the new mutant virus,” and “We are looking to improve the vaccine against mutations.”
“There are currently 4,000 mutant viruses in the world,” he said. “All pharmaceutical companies and laboratories such as Pfizer, Bioentech, Modena, Oxford and AstraZeneca are looking to improve their vaccines to ensure they are prepared for this mutant virus. There is” he explained.
Corona 19 virus is an RNA virus that mutates very often in the process of replicating genetic information. Since it is 100,000 times more likely to mutate than DNA virus, the Corona 19 virus created thousands of mutations in the process of spreading to the world last year. Experts are concerned that the mutations found in the UK and South Africa are highly contagious and the vaccine may not work well.
The UK launched an experiment to evaluate the immune response after vaccinating the US Pfizer at the first dose of AstraZeneca vaccine at the second dose. Initial data on the immune response is expected to come out around June.
In this test, we will also find out how the results differ when the vaccination interval is 4 weeks and 12 weeks.
Matthew Snape, a vaccine expert at the University of Oxford, who is leading the trial, said mixing different injections has proven to work for the Ebola vaccine. He said the vaccines will work, although their manufacturing techniques are different.
“In the end, all of this brings together the same target, the cells that make the spike protein,” he said. “That’s why we expect this combination of vaccines to trigger a good immune response.”
–
